Skip to main content

Advertisement

Table 3 Differences in cardiometabolic health risk indicators across gender and antipsychotic treatment groups

From: Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study

  BMI (kg/m2) Waist circumference (cm) Diastolic blood pressure Pulse CVD relative risk
MDa [95% CI] T p MDa [95% CI] T p MRb Z p MRb Z p MRb Z p
Gender 1.21 [0.46, 2.88] 1.44 .154 3.25 [-1.84, 8.34] 1.27 .208 46.24 (male) −2.22 .027* 44.76 (male) −1.15 .130 49.32 (male) −3.62 < .001***
34.45 (female) 36.67 (female) 29.89 (female)
Clozapine prescribed (yes Vs no) 0.85 [-1.41, 3.11] 0.75 .456 3.07 [-3.60, 9.74] 0.92 .363 41.52 (no) −0.02 .985 56.04 (yes) −2.52 .012* 55.71 (yes) −2.45 .014*
41.39 (yes) 38.51 (no) 8.57 (no)
Oral and LAI (combination Vs single route) 2.58 [0.71, 4.46] 2.74 .008** 4.30 [-1.60, 10.20] 1.45 .151 50.82 (combine) −1.96 .050 42.46 (single) −0.67 .505 53.68 (combine) −2.54 .011*
38.69 (single) 38.32 (combined) 37.83 (single)
1st and 2nd generation antipsychotics (combination Vs single class) 3.01 [0.77, 5.25] 2.67 .009** 2.98 [-4.13, 10.9] 0.83 .407 49.54 (combine) −1.28 .202 42.20 (single) −0.65 .519 59.50 (combine) −2.83 .005**
40.12 (single) 37.42 (combine) 38.41 (single)
  MDc [95% CI] F p MDc [95% CI] F p MRd H p MRd H p MRd H p
Number of antipsychotic types (one, two, three) 5.25 [0.73, 9.77] 4.93 .010* 5.43 [-9.13, 19.98] 0.47 1.000 49.44 (two) 3.83 .147 43.45 (one) 1.14 .564 37.19 (one) 6.71 .035*
(one vs three) (one, two, three) 38.50 (three) 38.23 (two) 47.52 (two)
38.19 (one) 34.75 (three) 63.50 (three)
Dosage of prescribed antipsychotics (>2 DDD, 1.1–2 DDD, ≤1 DDD) 3.94 [1.57, 6.30] 8.73 .001*** 9.73 [2.22, 17.24] 5.28 .007** 49.90 (>2) 7.77 .021* 42.66 (≤1) 0.13 .940 52.04 (>2) 9.41 .009**
(>2 vs 1.1–2) (>2 vs 1.1–2) 44.44 (1.1–2) 40.81 (>2) 42.90 (1.1–2)
2.79 [0.52, 5.06] 8.73 .011* 32.81 (≤1) 40.71 (1.1–2) 32.45 (≤1)
(>2 vs ≤1)
  1. CI confidence interval, MD mean difference, MR mean rank, BMI body mass index, CVD cardiovascular disease, DDD daily defined dose, LAI long acting intramuscular injection
  2. aIndependent sample T-test, bMann-Whitney U-test, c1-way ANOVA (Bonferroni-corrected post-hoc test), dKruskal-Wallis test
  3. * p < .05, ** p < .01, *** p < .001